var data={"title":"Mesalamine (mesalazine): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mesalamine (mesalazine): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6539?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mesalamine-mesalazine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mesalamine (mesalazine): Patient drug information&quot;</a> and <a href=\"topic.htm?path=mesalamine-mesalazine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mesalamine (mesalazine): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193412\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Apriso;</li>\n      <li>Asacol HD;</li>\n      <li>Canasa;</li>\n      <li>Delzicol;</li>\n      <li>Lialda;</li>\n      <li>Pentasa;</li>\n      <li>Rowasa;</li>\n      <li>SfRowasa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193413\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Asacol;</li>\n      <li>Asacol 800;</li>\n      <li>Mesasal;</li>\n      <li>Mezavant;</li>\n      <li>Pentasa;</li>\n      <li>Salofalk;</li>\n      <li>Teva-5 ASA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193456\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        5-Aminosalicylic Acid Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193417\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease, mild to moderate (treatment):</b> Oral: Pentasa (Canadian labeling; not in US labeling): Initial: 1 g 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease, mild to moderate (maintenance of remission):</b> Oral: Pentasa (Canadian labeling; not in US labeling): 1 g 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Distal ulcerative colitis or proctosigmoiditis, active mild to moderate (treatment):</b> Rectal: Retention enema: 4 g at bedtime, retained overnight, approximately 8 hours. <b>Note: </b>Duration of rectal therapy is 3 to 6 weeks; some patients may require rectal and oral therapy concurrently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Distal ulcerative colitis (maintenance of remission):</b> Rectal: Retention enema: Salofalk [Canadian product]: 2 g at bedtime daily or 4 g at bedtime every 2 to 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis (treatment):</b> Oral: Usual course of therapy is 6 to 8 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Asacol HD: 1.6 g 3 times daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Delzicol: 800 mg 3 times daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lialda: 2.4 or 4.8 g once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pentasa: 1 g 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Asacol: 800 mg to 3.2 g in divided doses daily; for severe active disease may increase to 4.8 g daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Asacol 800: 1.6 g 3 times daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mesasal: 1.5 to 3 g daily in 3 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mezavant: 2.4 to 4.8 g once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pentasa: 500 mg 4 times daily; may increase to 1 g 4 times daily if needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis (maintenance of remission):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apriso: 1.5 g once daily in the morning</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Delzicol: 1.6 g in 2 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lialda: 2.4 g once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pentasa: 1 g 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Asacol: 1.6 g daily in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mesasal: 1.5 g daily in 3 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mezavant: 2.4 g once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pentasa: 500 mg 4 times daily; may increase to 1 g 4 times daily if needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative proctitis, active:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Retention enema: 4 g at bedtime, retained overnight, approximately 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal suppository: 1,000 mg (1 suppository) rectally (retain for at least 1 to 3 hours) at bedtime for 3 to 6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Salofalk [Canadian product]: One 500 mg suppository in rectum 2 to 3 times daily or one 1,000 mg suppository in rectum once daily at bedtime; retained for at least 1 to 3 hours to achieve maximum benefit. Usual dose: 1 to 1.5 g daily until significant clinical response or remission. Taper off gradually; avoid abrupt discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24760495\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=mesalamine-mesalazine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mesalamine (mesalazine): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis (treatment):</b> Children &ge;5 years and Adolescents: Oral: Delzicol:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">17 to 32 kg: 800 mg in the morning and 400 mg in the evening for 6 weeks; maximum dose: 1,200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">33 to 53 kg: 1,200 mg in the morning and 800 mg in the evening for 6 weeks; maximum dose: 2,000 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">54 to 90 kg: 1,200 mg in the morning and 1,200 mg in the evening for 6 weeks; maximum dose: 2,400 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193418\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14637225\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be necessary since mesalamine is renally eliminated. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14637226\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193391\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delzicol: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pentasa: 250 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pentasa: 500 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Apriso: 0.375 g [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Enema, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SfRowasa: 4 g/60 mL (60 mL) [sulfite free; contains edetate disodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rowasa: 4 g [contains edetate disodium, potassium metabisulfite, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppository, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Canasa: 1000 mg (30 ea, 42 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asacol HD: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lialda: 1.2 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 800 mg, 1.2 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193376\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5940153\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enema, Rectal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pentasa: 1 g/100 mL, 4 g/100 mL [contains sodium acetate, sodium edetate, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Salofalk: 2 g/60 mL, 4 g/60 mL [contains edetate disodium, potassium metabisulfite, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppository, Rectal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pentasa: 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Salofalk: 500 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet Delayed Release, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asacol: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asacol 800: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mesasal: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pentasa: 500 mg, 1 g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, delayed and extended release: Mezavant: 1.2 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46780924\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asacol HD formulated <b>without</b> dibutyl phthalate (DBP) (NDC: 0023-5901-18) is available in the US as of May 2017.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asacol HD formulated <b>with</b> DBP (NDC: 00430-0783-27) may still be available in the marketplace and on pharmacy shelves.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193394\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apriso: Do not administer with antacids. Opening the capsule and placing the contents (delayed-release granules) on food with a pH &lt;6 is not expected to affect the release of mesalamine once ingested (data on file, Salix Pharmaceuticals Medical Information). There is no safety/efficacy information regarding this practice.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Delzicol: Swallow capsule whole with water; do not break, chew, crush, or cut. If a patient is unable to swallow the capsule, may open capsule and swallow capsule contents whole (do not cut, chew, break, or crush, or cut the contents).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pentasa: Swallow capsule whole; do not crush or chew; if a patient is unable to swallow the capsule, may open capsule and sprinkle the entire contents (controlled-release beads) onto yogurt or applesauce.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Swallow whole; do not break, chew, or crush.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asacol [Canadian product]: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asacol HD (product formulated without dibutyl phthalate [DBP]): Administer on an empty stomach (at least 1 hour before or 2 hours after a meal).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asacol HD (product formulated with DBP), Asacol 800 [Canadian product]: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lialda: Administer with a meal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mesasal [Canadian product]: Administer before meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mezavant [Canadian product]: Administer with a meal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pentasa [Canadian product]: Administer with meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal enema: Shake bottle well. Instruct patient to lie on left side with left leg extended and right leg flexed forward for balance, or in &ldquo;knee-chest&rdquo; position. Insert lubricated applicator tip into the rectum and point slightly toward the navel. Grasp bottle firmly and tilt so nozzle is aimed toward the back; squeeze slowly to instill medication. After administration, withdraw and discard bottle. Retain enemas for 8 hours or as long as practical.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppository: Remove foil wrapper; avoid excessive handling. Insert into rectum. Retain suppository for 1 to 3 hours or longer. Do not cut or break suppository.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193393\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Apriso: Maintenance of remission of ulcerative colitis in patients &ge;18 years</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Asacol HD: Treatment of moderately active ulcerative colitis in adults</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Delzicol: Treatment of mildly to moderately active ulcerative colitis in patients &ge;5 years; maintenance of remission of ulcerative colitis in adults </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Lialda, Pentasa: Treatment and maintenance of remission of mildly to moderately active ulcerative colitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: Treatment of active mild to moderate distal ulcerative colitis (suspension only), proctosigmoiditis (suspension only), or proctitis (suspension and suppository)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Asacol, Mezavant: Treatment and maintenance of remission of mildly- to moderately-active ulcerative colitis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Asacol 800: Treatment of moderately active ulcerative colitis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mesasal: Treatment and maintenance of remission of ulcerative colitis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pentasa: Treatment and maintenance of remission of mildly to moderately active ulcerative colitis; treatment and maintenance of remission of mild to moderate Crohn disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rectal: Treatment and maintenance of remission of distal ulcerative colitis (extending to splenic flexure) and as adjunctive therapy in more extensive disease (suspension only); treatment and maintenance of ulcerative proctitis (suppository only)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193463\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Mesalamine may be confused with mecamylamine, megestrol, memantine, metaxalone, methenamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Apriso may be confused with Apri</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Asacol may be confused with Ansaid, Os-Cal [DSC]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lialda may be confused with Aldara</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pentasa may be confused with Pancrease, Pangestyme</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193383\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects vary depending upon dosage form; frequency similar in adult and pediatric patients unless otherwise noted. Incidence usually on lower end with enema and suppository dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Eructation (&le;26%), abdominal pain (oral: 2% to 21%, children &amp; adolescents: 10%; rectal: 5%), constipation (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (children and adolescents: 15%; adults: 1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&le;9%), fatigue (&lt;3%), pain (&lt;3%), vertigo (&lt;3%), nervousness (&ge;2%), paresthesia (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&le;6%), alopecia (&lt;3%), acne vulgaris (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum triglycerides (&lt;3%), weight loss (children and adolescents: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (&le;8%), exacerbation of ulcerative colitis (&le;6%), flatulence (&le;6%), upper abdominal pain (1% to 5%), dyspepsia (&le;4%), nausea (&le;4%), lower abdominal pain (&lt;3%), gastroenteritis (&ge;2%), hemorrhoids (&ge;2%), tenesmus (&ge;2%), gastrointestinal hemorrhage (&lt;1% to &ge;2%), bloody diarrhea (children and adolescents: 2%), pancreatitis (children and adolescents: 2%), sclerosing cholangitis (children and adolescents: 2%), vomiting (&le;2%), rectal pain (rectal: 1% to 2%), abdominal distention (&ge;1%), anorectal pain (rectal: 1%; includes pain on insertion of enema tip), nausea and vomiting (1%), colitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria (&lt;3%), urinary frequency (&lt;1% to &ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hematocrit (&lt;3%), decreased hemoglobin (&lt;3%), rectal hemorrhage (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Cholestatic hepatitis (&lt;3%), increased serum transaminases (&lt;3%), hepatic insufficiency (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (1% to 5%), infection (&ge;2%), viral infection (children and adolescents: 2%; adenovirus)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (&le;6%), arthralgia (&lt;3%), arthropathy (&ge;2%), leg pain (rectal: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (&ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Decreased creatinine clearance (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (8%), sinusitis (children and adolescents: 7%; adults: &lt;1%), cough (children &amp; adolescents: 5%; adults: &lt;1%), dyspnea (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Intolerance syndrome (3%), fever (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal cramps (rectal), abnormal stools, abnormal T waves on ECG, acute renal failure, agranulocytosis, albuminuria, amenorrhea, anaphylaxis, anemia, angioedema, anorectal pain (rectal; discomfort), anorexia, anxiety, aplastic anemia, arthritis, blurred vision, bronchitis, chest pain, chills, cholecystitis, cholestatic jaundice, chronic renal failure, confusion, conjunctivitis, decreased libido, depression, diaphoresis, DRESS syndrome, drowsiness, drug fever, duodenal ulcer, dysgeusia, dysmenorrhea, dysphagia, dysuria, ear disease, ecchymoses, eczema, edema, emotional lability, eosinophilia, eosinophilic pneumonitis, epididymitis, erythema, erythema nodosum, esophageal ulcer, Eustachian tube congestion, exacerbation of asthma, eye pain, facial edema, fecal discoloration (rectal), fecal incontinence, frequent bowel movements (rectal), gastritis, gout, granulocytopenia, Guillain-Barr&eacute; syndrome, hepatic cirrhosis, hepatic failure, hepatic injury, hepatic necrosis, hepatitis, hepatotoxicity, hyperesthesia, hypermenorrhea, hypersensitivity pneumonitis, hypersensitivity reaction, hypertonia, hypomenorrhea, hypotension, idiopathic nephrotic syndrome, increased amylase, increased appetite, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, increased serum lipase, increased thirst, insomnia, interstitial nephritis, interstitial pneumonitis, interstitial pulmonary disease, intracranial hypertension, jaundice, Kawasaki-like syndrome, leg cramps, leukopenia, lichen planus, lupus-like syndrome, lymphadenopathy, malaise, male infertility (rectal), mastalgia, migraine, mucus stools (rectal), myalgia, myocarditis, nail disease, neck pain, nephrogenic diabetes insipidus, nephrotoxicity (rectal), neutropenia (rectal), oligospermia, oral candidiasis, oral mucosa ulcer, otalgia, painful defecation (rectal), palpitations, pancytopenia, perforated peptic ulcer, pericardial effusion, pericarditis, peripheral edema, peripheral neuropathy, pharyngitis, pharyngolaryngeal pain, pleurisy, pneumonitis, prurigo, pruritus, pruritus ani (rectal), psoriasis, pulmonary infiltrates, pulmonary fibrosis, pyoderma gangrenosum, rectal discharge (rectal), rectal polyp, renal disease (including minimal change nephropathy), renal insufficiency, renal failure, rheumatoid arthritis, skin photosensitivity, Stevens-Johnson syndrome, stomach discomfort (rectal), stomatitis, swelling of eye, systemic lupus erythematosus, tachycardia, thrombocythemia, thrombocytopenia, transverse myelitis, tremor, ulcerative colitis (rectal; pancolitis), urinary urgency, urticaria, uterine hemorrhage, vasodilatation, weakness, xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193397\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to mesalamine, aminosalicylates, salicylates, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe renal impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>); severe hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer, urinary tract obstruction, use in children &lt;2 years of age (Asacol, Asacol 800, Mesasal, Pentasa, Salofalk); hemorrhagic diathesis (Mesasal); patients unable to swallow intact tablet (Asacol, Asacol 800); renal parenchymal disease (Pentasa)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193380\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac hypersensitivity effects: Pericarditis and myocarditis (mesalamine-induced cardiac hypersensitivity reactions) have been reported. Use with caution in patients predisposed to these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Mesalamine-induced hypersensitivity reactions have been reported and may include internal organ involvement, such as hepatitis, hematologic abnormalities, and/or pneumonitis. Discontinue treatment for mesalamine-induced hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intolerance syndrome: May cause an acute intolerance syndrome (cramping, abdominal pain, bloody diarrhea; sometimes fever, headache, malaise, pruritus, rash, conjunctivitis); may be hard to discern from an exacerbation; discontinue immediately if syndrome occurs or is suspected. Symptoms usually abate if drug is discontinued. If rechallenge is performed to validate the hypersensitivity, use a reduced dose and only if clearly needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oligospermia: In males, oligospermia (rare, reversible) has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Renal impairment (including minimal change nephropathy, acute and chronic interstitial nephritis, nephrotic syndrome, and rarely renal failure) has been reported. A renal function evaluation is recommended prior to initiation of therapy and periodically during treatment. Mesalamine-induced nephrotoxicity should be suspected in patients developing renal impairment during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfasalazine hypersensitivity: Patients with hypersensitivity to sulfasalazine may react to mesalamine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with hepatic impairment; hepatic failure has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment, a history of renal disease, or those on nephrotoxic medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; uncontrolled studies and postmarketing reports suggest an increased incidence of blood dyscrasias (ie, agranulocytosis, neutropenia, pancytopenia) in patients &gt;65 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Apriso: Contains phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asacol HD (formulated without dibutyl phthalate [DBP]), Delzicol: Intact, partially intact, and/or tablet shells have been reported in the stool.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Canasa suppositories: Contain saturated vegetable fatty acid esters (contraindicated in patients with allergy to these components). May stain surfaces including clothing, other fabrics, flooring, painted surfaces, enamel, granite, marble and vinyl. Avoid contact with these surfaces.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rowasa enema: Contain metabisulfite salts that may cause severe hypersensitivity reactions (ie, anaphylaxis) in patients with sulfite allergies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rowasa, sfRowasa: May stain direct contact surfaces including clothing, other fabrics, flooring, painted surfaces, enamel, granite, marble and vinyl.  Choose a suitable location for product administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablets: Patients with pyloric stenosis or other organic or functional upper gastrointestinal obstructive disorders may have prolonged gastric retention of tablets, delaying the release of mesalamine in the colon.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Asacol HD: Safety and effectiveness beyond 6 weeks have not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bioequivalence: The Asacol HD 800 mg tablet has not been shown to be bioequivalent to two Delzicol 400 mg capsules. Two Delzicol 400 mg capsules have not been shown to be interchangeable or substitutable with one mesalamine 800 mg delayed-release tablet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299675\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193385\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9614&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparins (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: 5-Aminosalicylic Acid Derivatives may decrease the metabolism of Thiopurine Analogs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193387\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5304690\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Mesalamine is known to cross the placenta. An increased rate of congenital malformations has not been observed in human studies. Preterm birth, still birth and decreased birth weight have been observed; however, these events may also be due to maternal disease.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Dibutyl phthalate (DBP) may be an inactive ingredient in the enteric coating of some products (eg Asacol, Asacol HD); adverse effects in male rats were noted at doses greater than the recommended human dose. Refer to product labeling for current formulation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When treatment for inflammatory bowel disease is needed during pregnancy, mesalamine may be used, although products with DBP should be avoided (Habal 2012; Mottet 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193400\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Low concentrations of mesalamine (undetectable to 0.11 mg/L) and higher concentrations of the active metabolite (N-acetyl-5-aminosalicylic acid; 5 to 18.1 mg/L) have been detected in human breast milk. Based on these concentrations, the estimated exposure to the breast-feeding infant would be 0 to 0.017 mg/kg/day of mesalamine and 0.75 to 2.72 mg/kg/day of the active metabolite.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Adverse effects (diarrhea) in a breast-feeding infant have been reported while the mother received rectal administration of mesalamine within 12 hours after the first dose (Nelis 1989). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother. Some sources consider use of mesalamine to be safe while breast-feeding (Habal 2012; Mottet 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193401\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apriso: Do not administer with antacids.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193389\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (prior to and periodically during therapy); CBC (particularly in elderly patients); hepatic function; signs/symptoms of worsening acute intolerance syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193379\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Mesalamine (5-aminosalicylic acid) is the active component of sulfasalazine; the specific mechanism of action is unknown; however, it is thought that mesalamine modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193396\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rectal: Variable and dependent upon retention time, underlying GI disease, and colonic pH; Oral: Tablet: ~20% to 28%, Capsule: ~20% to 43%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Mesalamine (5-ASA): ~43%; N-acetyl-5-ASA: ~78%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and via GI tract to N-acetyl-5-aminosalicylic acid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 5-ASA and N-acetyl-5-ASA: Variable; ~ 25 hours (range: 2 to 296 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Apriso: ~4 hours; Delzicol: ~10 hours; Pentasa: ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: Pentasa, Salofalk [Canadian products]: 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Asacol HD (formulated with dibutyl phthalate [DBP]): 10 to 16 hours; Asacol HD (formulated without DBP): ~24 hours (mean); Lialda: 9 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Canadian products: Asacol: 7 hours; Asacol 800: 10 hours; Mesasal: ~7 hours; Mezavant: 8 hours (range: 4 to 34 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, suppository: Urine (primarily as N-acetyl-5-ASA, &le;12% as unchanged drug); feces (unabsorbed mesalamine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enema: Feces (primarily); urine (10% to 30%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193399\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Apriso Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 g (120): $577.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Pentasa Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (240): $874.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (120): $874.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Delzicol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (180): $765.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Enema</b> (Mesalamine Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (60 mL): $24.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Enema</b> (SfRowasa Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/60 mL (60 mL): $67.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Mesalamine-Cleanser Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (1): $171.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Rowasa Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (1): $476.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Canasa Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (30): $1,273.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Asacol HD Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (180): $1,854.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Lialda Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 g (120): $1,347.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Mesalamine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 g (120): $1,213.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (180): $1,397.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193402\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>5-ASA 400 (AR, PY);</li>\n      <li>Asacol (AE, BE, BH, CH, CY, DK, EG, ES, FI, GB, GR, HK, HR, IL, IT, JO, JP, KR, KW, LB, LU, LV, MT, MX, NL, NO, NZ, PK, PT, QA, SA, SE, SG, TW);</li>\n      <li>Asacolon (CO, IE);</li>\n      <li>Asakol (UA);</li>\n      <li>Asalit (BR);</li>\n      <li>Canasa (BD, CO);</li>\n      <li>Claversal (AT, BE, DE, ES, IT, LU, PT);</li>\n      <li>Colitofalk (BE, LU);</li>\n      <li>Coloncure (TW);</li>\n      <li>Huma-Col-Asa (HU);</li>\n      <li>Ibsol (LK);</li>\n      <li>Lialda (JP);</li>\n      <li>Lixacol (ES);</li>\n      <li>Mecolzine (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Mesacol (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Mesalin (KR);</li>\n      <li>Mesasal (AU, DK, NO, ZA);</li>\n      <li>Meslamin (BD);</li>\n      <li>Mezacol (AE, QA);</li>\n      <li>Mezavant (IE);</li>\n      <li>Mezavant XL (GB, HK, SG);</li>\n      <li>Octasa (GB);</li>\n      <li>Pentasa (AE, AU, BB, BE, BH, CH, CN, CY, DK, EG, ES, FR, GB, HK, HR, HU, IE, IQ, IR, IS, JO, JP, KW, LB, LU, LV, LY, MT, MY, NL, NO, OM, PH, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, VN, YE);</li>\n      <li>Pentasa Enema (NZ);</li>\n      <li>Pentasa SR (AE, BH, CY, EG, IL, IQ, IR, JO, KR, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Pentasa Tab (NZ);</li>\n      <li>Salofalk (AT, AU, BG, CH, CL, CN, CO, CZ, DE, EE, ES, GB, HK, HR, HU, ID, IE, KR, LK, LT, LV, MT, MY, NL, PE, PH, PL, RO, SG, SI, SK, TH, TR, UA, UY);</li>\n      <li>Salofalk Foam Enema (AU);</li>\n      <li>Suprimal (EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Apriso (mesalamine) extended-release capsules [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asacol HD (mesalamine) delayed-release tablets [prescribing information]. Rockaway, NJ: Warner Chilcott; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asacol HD (mesalamine formulated with DBP) delayed-release tablets [prescribing information]. Rockaway, NJ: Warner Chilcott; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canasa (mesalamine) rectal suppository [prescribing information]. Bridgewater, NJ: Aptalis Pharma; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crohn&rsquo;s &amp; Colitis Foundation of America (CCFA). Available at http://www.ccfa.org/resources/treating-children.html</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delzicol (mesalamine) [prescribing information]. Rockaway, NJ: Warner Chilcott; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM and Huang VW, &quot;Review Article: A Decision-Making Algorithm for the Management of Pregnancy in the Inflammatory Bowel Disease Patient,&quot; <i>Aliment Pharmacol Ther</i>, 2012, 35(5):501-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kamm MA, Sandborn WJ, Gassull M, et al, &ldquo;Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis,&rdquo; <i>Gastroenterology</i>, 2007, 132(1):66-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/17241860/pubmed\" target=\"_blank\" id=\"17241860\">17241860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo; <i>Am J Gastroenterol</i>, 2010, 105(3):501-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/20068560/pubmed\" target=\"_blank\" id=\"20068560\">20068560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lialda (mesalamine) [prescribing information]. Wayne, PA: Shire US Inc; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mesasal (5-aminosalicylic acid) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc.; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mezavant (mesalamine) [product monograph]. Toronto, Ontario, Canada: Shire Pharma Canada ULC; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mottet C, Vader JP, Felley C, et al, &quot;Appropriate Management of Special Situations in Crohn's Disease (Upper Gastro-Intestinal; Extra-Intestinal Manifestations; Drug Safety During Pregnancy and Breastfeeding): Results of a Multidisciplinary International Expert Panel-EPACT II,&quot; <i>J Crohns Colitis</i>, 2009, 3(4):257-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/21172284/pubmed\" target=\"_blank\" id=\"21172284\">21172284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelis GF, &quot;Diarrhoea Due to 5-Aminosalicylic Acid in Breast Milk,&quot;<i> Lancet</i>, 1989, 1(8634):383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-drug-information/abstract-text/2563532/pubmed\" target=\"_blank\" id=\"2563532\">2563532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pentasa (mesalamine) extended-release capsules [prescribing information]. Lexington, MA: Shire US Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pentasa (mesalamine) [product monograph]. North York, Ontario, Canada: Ferring Pharmaceuticals; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowasa (mesalamine) suspension [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    sfRowasa (mesalamine) rectal suspension [prescribing information]. Somerset, NJ: Meda; June 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9614 Version 192.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193412\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193413\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F193456\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F193417\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F24760495\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F193418\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14637225\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14637226\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193391\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F193376\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5940153\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46780924\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F193394\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F193393\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F193463\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193383\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193397\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193380\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299675\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193385\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193387\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5304690\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F193400\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F193401\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F193389\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193379\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F193396\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F193399\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193402\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9614|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mesalamine-mesalazine-patient-drug-information\" class=\"drug drug_patient\">Mesalamine (mesalazine): Patient drug information</a></li><li><a href=\"topic.htm?path=mesalamine-mesalazine-pediatric-drug-information\" class=\"drug drug_pediatric\">Mesalamine (mesalazine): Pediatric drug information</a></li></ul></div></div>","javascript":null}